Disclosed herein are imidazopyrimidine compounds of formula (I), wherein the substituents are as defined within the specification, processes for their preparation, compositions comprising said compounds and uses thereof. Said compounds are useful as phosphodiesterase inhibitors, in particular PDE10A, and as such are useful in the treatment of or prophylaxis of psychotic disorders, schizophrenia, positive, negative and/or cognitive symptoms associated with schizophrenia, delusional disorder, substance-induced psychotic disorder, anxiety disorders, panic disorder, obsessive/compulsive disorders, acute stress disorder, generalized anxiety disorder, drug addictions, movement disorders, Parkinson's disease, restless leg syndrome, cognition deficiency disorders, Alzheimer's disease, multi-infarct dementia, mood disorders, depression, bipolar disorders, neuropsychiatric conditions, psychosis, attention-deficit/hyperactivity disorder, attentional disorders, diabetes and related disorders, type 2 diabetes mellitus, neurodegenerative disorders, Huntington's disease, multiple sclerosis, stroke, spinal cord injury, solid tumors, haematological malignancies, renal cell carcinoma or breast cancer. Examples of particularly preferred compounds include: Isoxazole-5-carboxylic acid (2-phenyl-imidazo[1,2-a]pyrimidin-7-yl)-amide； 4,5,6,7-Tetrahydro-benzo[d]isoxazole-3-carboxylic acid (2-phenyl-imidazo[1,2-a]pyrimidin-7-yl)-amide； 5-(2-Phenyl-imidazo[1,2-a]pyrimidin-7-ylcarbamoyl)-3H-[1,2,3]triazole-4-carboxylic acid methyl ester； 1-Methyl-3-(pyrimidin-5-ylamino)-1H-pyrazole-4-carboxylic acid (2-phenyl-imidazo[1,2-a]pyrimidin-7-yl)-amide； 3,6-Dimethyl-pyridine-2-carboxylic acid (2-phenyl-imidazo[1,2-a]pyrimidin-7-yl)-amide； 2-Chloro-N-(2-phenyl-imidazo[1,2-a]pyrimidin-7-yl)-isonicotinamide.
